Immuno-oncology leverages the body's immune system to target cancer, providing novel and efficient treatment solutions. The seminar "Immuno-Oncology" highlights insights into immune mechanisms, therapeutic strategies, and novel research in cancer immunotherapy.".
This class of treatments consists of immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines, and adoptive cell transfer, all aiming to make the immune system more effective at recognizing and destroying tumor cells. By targeting tumor-specific antigens and manipulating immune responses, immuno-oncology therapies can cause long-lasting responses, even in patients with resistant or advanced cancers.
The session discusses the combination of immunotherapy with standard therapies such as chemotherapy, radiation, and targeted therapy to enhance response and break resistance. Biomarker-based patient selection, combination, and immune monitoring are imperative for maximizing outcomes and mitigating adverse effects. The progress in genomics, bioinformatics, and clinical trial design is propelling the next-generation immunotherapies.
Participants will learn the biology, clinical use, and the way forward for immuno-oncology. This session highlights how harnessing the power of the immune system offers individualized, effective, and life-transforming strategies in cancer management, enhancing survival, quality of life, and the practice of contemporary oncology treatment.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
